BioNexus Gene Lab Corp Q1 2025 10-Q Filing
Ticker: BGLC · Form: 10-Q · Filed: May 15, 2025 · CIK: 1737523
| Field | Detail |
|---|---|
| Company | Bionexus Gene Lab CORP (BGLC) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, genomic-screening, investment-holding
TL;DR
BioNexus Gene Lab Corp Q1 2025 10-Q filed. Investment holding & genomic screening. Subsequent event noted.
AI Summary
BioNexus Gene Lab Corp filed a 10-Q for the period ending March 31, 2025. The company's business activities include investment holding and provision for genomic screening services. A subsequent event occurred between April 1, 2025, and April 2, 2025.
Why It Matters
This filing provides insight into BioNexus Gene Lab Corp's financial performance and operational activities for the first quarter of 2025, including any significant post-period events.
Risk Assessment
Risk Level: medium — The filing is a standard quarterly report, but the nature of the business (gene lab) and potential for future events requires a medium risk assessment.
Key Numbers
- 1307508 — Total Assets (estimated) (This number appears in the filing and likely represents a key financial metric for the period.)
- 0.1 — Current Ratio (estimated) (This value, appearing multiple times, might indicate liquidity.)
Key Players & Entities
- BioNexus Gene Lab Corp (company) — Filer of the 10-Q
- 0001737523 (company) — Central Index Key for BioNexus Gene Lab Corp
- 20250331 (date) — End of the reporting period
- 20250515 (date) — Filing date
- KUALA LUMPUR (location) — City of business and mail address
FAQ
What were the primary revenue streams for BioNexus Gene Lab Corp during Q1 2025?
The filing indicates 'ProvisionForGenomicScreeningServicesMember' and 'InvestmentHoldingMember' as key business activities, suggesting these are primary areas of operation and potential revenue.
What is the significance of the subsequent event noted between April 1, 2025, and April 2, 2025?
The filing marks 'us-gaap:SubsequentEventMember' for the period of April 1, 2025, to April 2, 2025, indicating a material event occurred after the balance sheet date but before the report's issuance.
What is BioNexus Gene Lab Corp's fiscal year end?
The company's fiscal year ends on December 31st, as indicated in the filing.
Where is BioNexus Gene Lab Corp headquartered?
The company's business and mail address is listed as 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR, N8, 59200.
What type of services does BioNexus Gene Lab Corp primarily offer?
The Standard Industrial Classification code '8071' indicates 'SERVICES-MEDICAL LABORATORIES', and the filing specifically mentions 'ProvisionForGenomicScreeningServicesMember'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding BioNexus Gene Lab Corp (BGLC).